About this trial
Osteoarthritis (OA) and sarcopenia are two highly prevalent, interconnected geriatric syndromes that often coexist, leading to a condition termed "osteosarcopenia". Globally, the pooled prevalence of sarcopenia in patients with knee OA is estimated at approximately 25.07%, significantly higher than in the general population.
Eligibility criteria
Qualifiers
Adults aged 40 years and older diagnosed with knee OA based on the American College of Rheumatology (ACR) criteria.
Patients who are willing to participate and provide informed written consent.
Disqualifiers
Inflammatory arthritis: patients with rheumatoid arthritis, gouty arthritis, or systemic lupus erythematosus (SLE) to avoid confusion with inflammatory muscle wasting.
Physical Limitations: amputees or those with severe physical deformities preventing gait speed tests or handgrip measurement.
Patients with cardiac pacemakers or implanted electronic devices (as these interfere with Bioelectrical Impedance Analysis (BIA)).
Severe Comorbidities: end-stage renal or hepatic disease, advanced malignancy or cachexia.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Locations
1Sponsors and collaborators
Assiut University
Lead sponsor